Running an immuno-oncology trial comes down to a series of decisions made under uncertainty. Which biomarker strategy will best support proof-of-concept, how to design endpoints that hold up under novel modalities, and how to manage immune-related toxicity profiles that don’t follow conventional rules. Worldwide Clinical Trials partners with sponsors from early proof-of-concept through regulatory approval, bringing precision, speed, and scientific rigor to every program. This includes expertise across cell therapies, bispecifics, gene therapies, and novel checkpoint inhibitors, biomarker-driven development strategies, and immune-related safety management spanning CRS, ICANS, TLS, and delayed reactions. Because oncology expertise is embedded across all functions and the team averages 11+ years of experience with a 90%+ retention rate, studies are led by seasoned professionals who understand the complexities of oncology science and trial execution—so you can move fast with confidence and scale without disruption.
Read our fact sheet to learn more about our immuno-oncology capabilities, including:
- 100+ IO studies in the last five years with 13,300+ patients enrolled, representing more than 45% of our active oncology portfolio across solid tumors and hematologic malignancies
- Next-generation modality experience spanning cell therapies (CAR-T, TILs, autologous and allogeneic), multi-specific antibodies, tumor microenvironment remodelers, oncolytic viruses and vaccines, gene therapies, and novel checkpoint inhibitors
- Complex study designs and novel endpoints including iRECIST, mTPI, and BOIN, with biomarker-driven development strategies and coordination of multiple vendors, complex trial logistics, and specialized drug handling
- Global footprint across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa, with a biotech mindset that brings the agility and responsiveness needed to meet critical oncology milestones from FIH through registration
